ScotCRemickMD

Oncology • Scarborough, ME

Cancer Center Director at Mary Babb Randolph Cancer Center at West Virginia University

Join to view full profile

Dr. Remick is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Remick's full profile

Already have an account?

Office
100 Campus Dr
Unit 121
Scarborough, ME 04074
Phone+1 207-396-7760

Fax+1 207-396-8500

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1985 - 1987
Johns Hopkins UniversityResidency, Internal Medicine, 1982 - 1985
New York Medical CollegeClass of 1982

Certifications & Licensure

ME State Medical License 2015 - 2026
WV State Medical License 2007 - 2017
OH State Medical License 1996 - 2010
WI State Medical License 1985 - 2007
NY State Medical License 1988 - 1998
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Bleomycin in Treating Patients With Non-Hodgkin's Lymphoma Start of enrollment: 1997 Jul 01
Completed
Phase 2
Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas Start of enrollment: 1997 Jul 01
Terminated
Phase 2
Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease Start of enrollment: 1997 Jul 01
Completed
Phase 2
Combretastatin A4 Phosphate in Treating Patients With Advanced Solid Tumors Start of enrollment: 1998 Sep 01
Completed
Phase 1
Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 1999 Jan 01
Completed
Phase 2
Chemotherapy, Filgrastim, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Start of enrollment: 1998 Jun 01
Withdrawn
Phase 2
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck Start of enrollment: 2000 May 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Apr 01
Completed
Phase 1
Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Jul 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer Start of enrollment: 1997 May 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Dec 01
Completed
Phase 1
Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma Start of enrollment: 2001 Nov 01
Completed
Phase 1
Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin Start of enrollment: 2001 Aug 01
Terminated
Phase 1
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Start of enrollment: 2002 Jul 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma Start of enrollment: 1998 Mar 01
Completed
Phase 2
Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma Start of enrollment: 2009 Jan 01
Withdrawn
Phase 2
Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation Start of enrollment: 2010 Oct 12
Completed
Phase 2
Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation Start of enrollment: 2014 Jan 20
Completed
Phase 2
1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX Start of enrollment: 2012 Feb 01
Terminated
Phase 2
Prospective Study of Lymphoproliferative Diseases
Withdrawn
Unrelated Umbilical Cord Blood (UBC)Transplantation Start of enrollment: 2009 Feb 03
Completed
Not Applicable
Symptom Management Implementation of Patient Reported Outcomes in Oncology Start of enrollment: 2019 Jul 25
Active, not recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

22 citations
Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer
Afshin Dowlati, Nathan Levitan, Nahida H. Gordon, Charles L. Hoppel, David M. Gosky
Cancer Chemotherapy and Pharmacology. 2001-01-01
24 citations
Phase I Clinical and Pharmacokinetic Study of Rebeccamycin Analog NSC 655649 Given Daily for Five Consecutive Days
Afshin Dowlati, Charles L. Hoppel, Stephen T. Ingalls, Susan Majka, Xiaolin Li
Journal of Clinical Oncology. 2001-04-15
691 citations
Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.
Nathan Levitan, Afshin Dowlati, Scot C. Remick, Hassan I. Tahsildar, Lynn D. Sivinski
Medicine. 1999-09-01

Press Mentions

New Grant Will Broaden Access to Clinical Trials for Cancer Patients in Rural MaineSeptember 5th, 2019
BriefsJune 11th, 2018
Expanding Access to Cutting Edge Cancer Care in MaineJuly 11th, 2017
Join now to see all

Grant Support

Developing Research Capacity For AIDS Malignancy In KenyaNational Cancer Institute2010–2011
Epothilone B Analogue BMS-247550 In PTS With Malignancies &Liver DysfunctionNational Center For Research Resources2006
17-Allylamino-17 Demethoxygeldanamycin (17-Aag) W/Paclitaxel In Adv Solid TumorsNational Center For Research Resources2006
Foreign Accrual For 5u10ca062502 - Phase I U01 2006 Load RemickNational Cancer Institute2006
Combretastatin/Doxorubicin/Cisplatin For Patients With Thyroid CancerNational Center For Research Resources2005–2006
Combretastatin A-4 Phosphate In Advanced Anaplastic Thyroid CarcinomaNational Center For Research Resources2005–2006
Bryostatin 1 + Vincristine In Non-Hodgkin'S Lymphoma Post TransplantNational Center For Research Resources2005–2006
17-Dimethylaminoethylamino-17demethoxygeldanamycin In Advanced Solid TumorsNational Center For Research Resources2005–2006
PS-341 In Patients With Advanced Malignancies And Renal DysfunctionNational Center For Research Resources2004–2006
Cwru/Uhicc Phase I Trials Of Anticancer AgentsNational Cancer Institute1998–2006
STI571 In Adv Malignancies Amp;Varying Degrees Of Renal DysfunctionNational Center For Research Resources2005
Silicone Phthalocyanine 4 (PC4) Photodynamic Therapy For Cutaneous MalignanciesNational Center For Research Resources2005
Fenretinide + Paclitaxel + Cisplatin For Advanced Solid TumorsNational Center For Research Resources2005
Epothilone B Analogue BMS-247550 In PTS With Malignancies And Liver DysfunctionNational Center For Research Resources2005
Thalidomide And Docetaxel For Advanced MalignanciesNational Center For Research Resources2004–2005
CCM AIDS Associated Malignancies Clinical Trials UnitNational Cancer Institute1999–2005
SU5416 And Paclitaxel In Recurrent Or Metastatic Carcinoma Of The Head And NeckNational Center For Research Resources2004
STI571 In PTS With Advanced Malignancies &Varying Levels Of Liver DysfunctionNational Center For Research Resources2004
STI571 In PTS With Advanced Malignancies &Varying Degrees Of Renal DysfunctionNational Center For Research Resources2004
Silicon Phthalocyanine 4 (PC4) + Photodynamic Therapy For Cutaneous MalignanciesNational Center For Research Resources2004
Oxaliplatin, Irinotecan, And Capecitabine In Solid TumorsNational Center For Research Resources2004
Combretastatin A-4 Phosphate In Advanced Anaplastic Carcinoma Of The ThyroidNational Center For Research Resources2004
Bryostatin 1+Vincristine In Non-Hodgkin'S Lymphoma PTS Post TransplantationNational Center For Research Resources2004
Oral Chemotherapy In Aids-Related NHL In Uganda &KenyaNational Cancer Institute2002–2003
Oxi 104 In Combination W/ Cisplatin In Patients W/ Advanced CancerNational Center For Research Resources1999–2002
CA4P (INTRAVENOUS) In Patients W/ Advanced CancerNational Center For Research Resources1999–2002
Bryostatin 1 &Vincristine In B Cell MalignanciesNational Center For Research Resources1999–2002
Core--InternationalNational Institute Of Allergy And Infectious Diseases1998–2002
Rebeccamycin Analog Given 5 Consecutive Days In Patients With Solid TumorsNational Center For Research Resources1998–2002
Oral Chemotherapy In AIDS Related NHL In Uganda &KenyaNational Cancer Institute2001
Core--Clinical Trials Support FacilityNational Cancer Institute1996–2000
Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1993–1996
Cooperative Oncology GroupNational Cancer Institute1994
Aids-Related CNS LymphomaNational Cancer Institute1993–1994
Eastern Cooperative Oncology GroupNational Cancer Institute1992–1993

Professional Memberships

American Society of Clinical Oncology - ASCO
Member